A phase 3, multicenter, double-blind, randomized, placebo-controlled clinical trial to verify the efficacy and safety of ansofaxine (LY03005) for major depressive disorder

Major depressive disorder (MDD) is the most prevalent form of depression and is becoming a great challenge for public health and medical practice. Although first-line antidepressants offer therapeutic benefits, about 35% of depressed patients are not adequately treated, creating a substantial unmet...

Descripción completa

Detalles Bibliográficos
Autores principales: Mi, Weifeng, Di, Xiaolan, Wang, Yiming, Li, Huafang, Xu, Xiufeng, Li, Lehua, Wang, Huaning, Wang, Guoqiang, Zhang, Kerang, Tian, Feng, Luo, Jiong, Yang, Chanjuan, Zhou, Yunfei, Xie, Shiping, Zhong, Hua, Wu, Bin, Yang, Dong, Chen, Zhenhua, Li, Yi, Chen, Jindong, Lv, Shuyun, Yi, Qizhong, Jiang, Zhiwei, Tian, Jingwei, Zhang, Hongyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171157/
https://www.ncbi.nlm.nih.gov/pubmed/37164957
http://dx.doi.org/10.1038/s41398-023-02435-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171157/
https://www.ncbi.nlm.nih.gov/pubmed/37164957
http://dx.doi.org/10.1038/s41398-023-02435-0

Ejemplares similares